Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions

Official Title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Topically Administered LUT014 in Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions

Keywords

EGFRI Induced Acneiform Lesions, EGFRI, Acneiform, Acneiform lesions, Acneiform rash, EGFRI induced skin toxicities, LUT014, LUT014 Gel (Dose 1), LUT014 Gel (Dose 2)

Eligibility

Locations

  • UCLA accepting new patients
    Santa Monica California 90404 United States
  • Innovative Clinical Research Institute accepting new patients
    Glendale California 91204 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Lutris Pharma Ltd.
ID
NCT04759664
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 117 study participants
Last Updated